Emodin induces Panc-1 cell apoptosis via declining the mitochondrial membrane potential

Jinxiang Liu, Jianhong Zhang, Honghai Li, Fu-ji Lai, Kangjie Chen, Hui Chen, Luo Jiang, Hongchun Guo, Zhaohong Wang, Sheng‐Zhang LinOncology 2012 · DOI

Abstract

This study investigates the therapeutic potential of emodin, a natural compound derived from traditional Chinese medicine, against human pancreatic cancer (Panc-1 cells). Through both in vitro and in vivo experiments, we demonstrate that emodin inhibits cell proliferation and induces apoptosis by triggering a decline in mitochondrial membrane potential (MMP). Our findings suggest that a moderate dose of emodin effectively reduces tumor growth while maintaining the overall health of the subject, offering a promising alternative or adjunct to current chemotherapy.

Introduction

Pancreatic cancer remains a significant clinical challenge due to its high mortality rate and limited response to standard treatments like gemcitabine. The search for more effective and less toxic compounds has led to the investigation of emodin (1,3,8-trihydroxyl-6-methyl anthraquinone). While its anti-cancer properties have been noted in other malignancies, its specific impact on pancreatic cancer—particularly the role of mitochondrial pathways—requires detailed exploration.

Methods

Human Panc-1 cells were treated with emodin concentrations ranging from 0 to 80 µmol/l. Cell proliferation was assessed via MTT assay, while apoptosis and mitochondrial membrane potential (MMP) were analyzed using flow cytometry (Annexin V/PI staining) and JC-1 staining, respectively. For in vivo studies, nude mice with orthotopically implanted Panc-1 tumors were treated with varying doses of emodin (10–80 mg/kg) via intraperitoneal injection. Tumor size, body weight, and appetite (feeding stuff intake) were monitored.

Results

Inhibition of Cell Proliferation

Emodin exhibited a clear dose- and time-dependent inhibitory effect on Panc-1 cell proliferation. In vitro results showed that 40 µmol/l of emodin inhibited growth by approximately 54.7% after 72 hours.

Induction of Apoptosis

Flow cytometric analysis revealed a significant increase in the apoptotic rate of Panc-1 cells as emodin concentration increased. This was further confirmed in vivo through TUNEL assays of tumor tissues.

Figure 2: Emodin induces apoptosis in Panc-1 cells in a dose-dependent manner, as shown by Annexin V/PI flow cytometry and quantified apoptotic rates.

Mechanism: Decline in Mitochondrial Membrane Potential (MMP)

The primary mechanism of emodin-induced apoptosis appears to be the disruption of mitochondrial integrity. JC-1 staining showed a shift from red fluorescence (healthy mitochondria) to green fluorescence (cytoplasmic monomers), indicating a significant decline in MMP. This dissipation of membrane potential triggers the release of pro-apoptotic factors into the cytoplasm.

Figure 4: Dose-dependent decline in the fluorescence ratio of Red to Green, indicating a loss of mitochondrial membrane potential (MMP) following emodin treatment.

In Vivo Efficacy and Safety

In the orthotopic mouse model, emodin treatment significantly reduced tumor diameters compared to the control group. Notably, the study identified a therapeutic "sweet spot": while the highest dose (E80) was effective, it caused a sharp decline in appetite. The E40 group (40 mg/kg) achieved high apoptosis rates without significantly compromising the mice's feeding behavior or overall living state.

Conclusion

Emodin induces apoptosis in pancreatic cancer cells by destabilizing the mitochondrial membrane potential. Its ability to inhibit tumor growth at moderate doses without severe systemic toxicity makes it a compelling candidate for further clinical development in the treatment of pancreatic cancer.

Summary updated

Abstract

In this study, we investigated the apoptotic effect of emodin on human pancreatic cancer cell line Panc-1 in vitro and in vivo as well as the possible mechanisms involved. In vitro, human pancreatic cancer cell line Panc-1 was exposed to varying concentrations of emodin (0, 10, 20, 40 or 80 µmol/l). Then the mitochondrial membrane potential (MMP) was analyzed by JC-1 staining, cell apoptosis was analyzed by flow cytometry (FCM) and cell proliferation was analyzed by MTT. In vivo, nude mice orthotopically implanted were randomly divided into five groups to receive treatments by different doses of emodin: control group (normal saline 0.2 ml), E10 group (emodin 10 mg/kg), E20 group (emodin 20 mg/kg), E40 group (emodin 40 mg/kg) and E80 group (emodin 80 mg/kg). Each mouse was treated 5 times by intraperitoneal injection of emodin every 3 days. During the treatment, the feeding stuff was recorded. One week after the last treatment, we recorded the body weight and the maximum diameter of tumor in each group before the mice were sacrificed. Then the cell apoptosis of the tumor was tested by TUNEL assay. The results in vitro showed that the MMP of the cells declined and the apoptosis rate increased with the emodin concentration increasing and the cell proliferation of each group was inhibited in a dose- and time-dependent manner by emodin. The feeding stuff curve did not decline significantly in E40 group and the apoptosis rate of the tumor cells in this group was higher than the lower-dose groups. Taken together, our results demonstrate that emodin may induce the pancreatic cancer cell apoptosis via declining the MMP and a moderate dose of emodin improved the living state of the model mice.
BibTeX
@inproceedings{liu2012emodin,
  author = {Jinxiang Liu and Jianhong Zhang and Honghai Li and FU-JI LAI and Kangjie Chen and Hui Chen and Luo Jiang and Hongchun Guo and Zhaohong Wang and Sheng‐Zhang Lin},
  title = {{Emodin induces Panc-1 cell apoptosis via declining the mitochondrial membrane potential}},
  booktitle = {Oncology},
  year = {2012},
  doi = {10.3892/or.2012.2042},
}
Figure